Momenta receives patent for methods to evaluate enoxaparin

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,816,144, entitled "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles or Chain Mapping". The patent includes claims to methods of analyzing and processing enoxaparin by analyzing chain sequence information.

"This patent adds to our intellectual property estate related to the characterization of enoxaparin," said Craig Wheeler, President and CEO of Momenta. "We believe this patent strengthens our portfolio of patents and pending applications that provide intellectual property protection around enoxaparin sodium injection USP, also known as generic Lovenox®."